Concluding his discussion on Parkinson disease OFF episodes management, Peter LeWitt, MD, shares practical advice regarding use of on-demand therapy.
A discussion about nusinersen, which acts on the SMN2 gene, and the significance of the results of the ENDEAR clinical trial, where 50% of patients were defined as responders.
When to use pacemakers and defibrillators for patients with cardiac amyloidosis disease subtypes.
Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Meeting reviewing first-line ocrelizumab compared to glatiramer acetate and dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis.
Emma Ciafaloni, MD, provides an overview of Duchenne muscular dystrophy, including common signs and symptoms.
Sven Meuth, MD, PhD, reviews the mechanism of action of interferon and its long-standing use in relapsing multiple sclerosis.
Dr James Wymer explains what spinal muscular atrophy is and discusses how the disease typically presents in newly diagnosed patients.
Shared insight on the open-label extension trial that analyzed long-term safety and efficacy with cannabidiol in patients with Dravet syndrome.
SAP Partner Banner